Pipeline
Learn more about our investigational RNAi therapeutics in various stages of clinical development and their disease targets.
Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam pipeline therapeutics that are out-licensed are not represented on this page. For further information, please see Alnylam's Clinical Development Pipeline.
For more information on any of our pipeline assets or clinical trials, please connect with an MSL or visit our clinical trials site.
Phase 3 Studies
Nucresiran*
ATTR Amyloidosis with Polyneuropathy
Nucresiran*
ATTR Amyloidosis with Cardiomyopathy
Zilebesiran*1
Hypertension
Zilebesiran + REVERSIR*1
Hypertension
Phase 2 Studies
ALN-4324 (GRB14)*
Type 2 Diabetes Mellitus
Mivelsiran (ALN-APP)*
Cerebral Amyloid Angiopathy (CAA)
Mivelsiran (ALN-APP)*
Alzheimer’s Disease
ALN-6400 (PLG)*
Hereditary Hemorrhagic Telangiectasia
ALN-6400 (PLG)*
Von Willebrand Disease
Phase 1 Studies
ALN-2232 (ACVR1C)*
Obesity & Weight Management
ALN-6222 (INHBE)*
Obesity & Weight Management
ALN-HTT02*1
Huntington's Disease
ALN-5288 (MAPT)*1
Alzheimer's Disease
ALN-BCAT*
Hepatocellular Carcinoma
ALN-4285*
Healthy Volunteers
ALN-4915*
Healthy Volunteers
